Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asthma: future directions.

Patricia Leonard1, Sanjiv Sur

  • 1Department of Allergy and Immunology, University of Texas Medical Branch, MRB 8.104, 301 University Boulevard, Galveston, TX 77555, USA.

The Medical Clinics of North America
|November 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting CXCR1/2 suppresses T<sub>H</sub>2/T<sub>H</sub>17 cell responses and inhibits dual-pathology allergic lung inflammation.

The journal of allergy and clinical immunology. Global·2026
Same author

Single-nucleus RNA sequencing identifies conserved structural cell programs in allergic lung inflammation.

The journal of allergy and clinical immunology. Global·2026
Same author

STING stimulates recruitment of inflammatory cells and airway fibrosis in chronic allergic airway inflammation.

The Journal of allergy and clinical immunology·2025
Same author

Allosteric inhibition of CXCR1 and CXCR2 abrogates Th2/Th17-associated Allergic Lung Inflammation in Mice.

bioRxiv : the preprint server for biology·2024
Same author

The DNA glycosylase NEIL2 is protective during SARS-CoV-2 infection.

Nature communications·2023
Same author

Reply to chicken or the egg: an unusual presentation of Crohn disease.

Internal medicine journal·2022
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Inhaled corticosteroids are the standard asthma treatment but haven't stopped rising cases. New, more effective asthma medications are in development to address this growing health and financial burden.

Area of Science:

  • Pulmonology
  • Allergy and Immunology
  • Pharmacology

Background:

  • Asthma remains a significant global health issue with increasing morbidity and mortality.
  • Inhaled corticosteroids (ICS) are the current standard of care due to safety and efficacy but have not curbed the asthma epidemic.
  • The substantial financial cost of asthma further drives the need for improved treatments.

Purpose of the Study:

  • To review the current landscape of asthma treatment and the urgent need for novel therapeutic agents.
  • To highlight the ongoing research and development of new medications for allergic diseases and asthma.
  • To discuss the economic factors motivating the search for more effective asthma therapies.

Main Methods:

  • Review of existing literature on asthma prevalence, treatment efficacy, and drug development pipelines.

Related Experiment Videos

  • Analysis of the economic impact of asthma on society.
  • Compilation of data on investigational drugs for asthma treatment.

    • Main Results:

    • Despite decades of ICS use, asthma prevalence and mortality continue to rise.
    • Significant financial burden associated with asthma management necessitates new treatment strategies.
    • Numerous novel drug candidates are under investigation, promising expanded therapeutic options.

    Conclusions:

    • Current inhaled corticosteroids, while effective for individual symptom management, have not halted the overall asthma epidemic.
    • The development of new asthma medications is crucial to address unmet clinical needs and reduce the societal cost of the disease.
    • Future advancements in pharmacotherapy are expected to provide millions of asthma patients with enhanced disease control.